💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Mitoxantrone

CHEMBL58 Phase 4 Approuvé Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
444.5 g/mol
LogP
1.0
Phase
4

This chemotherapy and immunosuppressant drug interferes with DNA replication, causing cancer cells and overactive immune cells to die. It is used to treat certain leukemias, breast cancer, and aggressive forms of multiple sclerosis.

Masse moléculaire

444,5000 g/mol

LogP

1,00

TPSA

163,00 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Pain Management Non-Small Cell Lung Cancer Multiple Sclerosis Lymphoma Breast Cancer Chronic Pain Prostate Cancer Colorectal Cancer Leukemia

Mécanisme d'action

Suppresses the immune system by inhibiting T-cell activation, lymphocyte proliferation, or cytokine production. This prevents immune-mediated tissue damage and graft rejection.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Suppresses the immune system by inhibiting T-cell activation, lymphocyte proliferation, or cytokine production. This prevents immune-mediated tissue damage and graft rejection.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21

                

                

                
                

                    
InChI

                    
InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H28N4O6

                    

                    
                    

                        
HBD / HBA

                        
8 / 10

                    

                    
                    

                        
Liaisons Rotatives

                        
12

                    

                    
                    
                    

                        
Atomes Lourds

                        
32

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
This chemotherapy and immunosuppressant drug interferes with DNA replication, causing cancer cells and overactive immune cells to die. It is used to treat certain leukemias, breast cancer, and aggressive forms of multiple sclerosis.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Suppresses the immune system by inhibiting T-cell activation, lymphocyte proliferation, or cytokine production. This prevents immune-mediated tissue damage and graft rejection.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Mitoxantrone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL58.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 4212.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.